Fact-checked by Grok 2 weeks ago

Tachyphylaxis

Tachyphylaxis is a pharmacological phenomenon characterized by the rapid diminution or loss of response to a drug or physiologically active agent after a few repeated administrations over a short period, often within minutes to hours.^[1] This acute desensitization differs from tolerance, which develops more gradually over days or weeks through adaptive changes like altered drug metabolism or receptor downregulation.^[2] In essence, tachyphylaxis reflects an immediate adaptive response at the cellular level, preventing sustained overstimulation by the agent.^[3] The mechanisms underlying tachyphylaxis typically involve receptor-level adaptations, such as desensitization (uncoupling of the receptor from downstream signaling pathways) or, in some cases, transient changes in receptor density without full downregulation.^[4] For instance, with indirect-acting sympathomimetics like ephedrine, tachyphylaxis arises from rapid depletion of presynaptic neurotransmitter stores, limiting further release upon repeated dosing.^[4] Unlike tolerance, the effect often cannot be readily overcome by increasing the dose, and it may resolve quickly upon drug withdrawal.^[1] Tachyphylaxis is clinically significant across various drug classes, impacting efficacy in acute and chronic treatments. Common examples include nitrates (e.g., nitroglycerin for angina, due to sulfhydryl group depletion^[5]), beta-adrenergic agonists and blockers, H2-receptor antagonists for acid suppression, and certain antidepressants like mirtazapine, where sedative effects wane rapidly.^[6]^[4] It poses challenges in clinical management, often necessitating drug holidays, alternative therapies, or combination regimens to restore responsiveness.^[7] Understanding tachyphylaxis is crucial for optimizing dosing schedules and minimizing therapeutic failures in pharmacology.^[8]

Definition and Characteristics

Definition

Tachyphylaxis is defined as the acute development of tolerance to the effects of a drug following repeated doses, leading to a diminished clinical response without an increase in dose. The term derives from the Greek words tachys (rapid) and phylaxis (protection), reflecting the rapid onset of reduced responsiveness. This phenomenon typically manifests within minutes to hours after initial administration, distinguishing it from chronic tolerance, which develops over days or weeks through adaptive changes.^[9]^[10] The rapid loss of drug efficacy associated with tachyphylaxis can compromise therapeutic outcomes in acute clinical settings, such as emergency treatments for hypotension or bronchospasm, often necessitating dose adjustments, alternative agents, or temporary discontinuation to restore sensitivity. For instance, repeated dosing may result in attenuated effects, prompting clinicians to switch drugs to maintain efficacy.^[11]^[12] Tachyphylaxis has been observed in early 20th-century pharmacological studies involving adrenaline (epinephrine) and ergotamine, where repeated administrations led to progressively weaker physiological responses, such as diminished vasoconstriction or uterine contraction. These observations contributed to understanding acute desensitization in drug therapy.^[13] Tachyphylaxis is distinguished from tolerance primarily by its rapid onset and reversibility, occurring within hours to days following repeated drug administration, whereas tolerance develops more gradually over days to weeks and often involves adaptive changes such as increased drug metabolism or receptor downregulation that may require longer periods for reversal.^[1]^[2] For instance, in the case of indirect-acting sympathomimetics like amphetamines, tachyphylaxis arises from quick depletion of neurotransmitter stores, leading to a swift loss of effect that can be restored shortly after discontinuation, in contrast to the chronic adaptations seen in opioid tolerance.^[8] Desensitization, while related, encompasses a broader reduction in receptor responsiveness to agonists, often at the cellular level through mechanisms like phosphorylation, and may not always manifest as a whole-organism loss of therapeutic effect; tachyphylaxis, however, specifically denotes the acute diminution of the drug's overall pharmacological response in the intact organism, independent of changes in receptor sensitivity thresholds.^[14] This distinction is evident in beta-agonist use for asthma, where desensitization might involve localized receptor uncoupling, but tachyphylaxis reflects the observable decline in bronchodilation across the system without necessarily implying altered detection limits.^[15] In psychiatric applications, such as with antidepressants, tachyphylaxis—sometimes termed "poop-out"—must be differentiated from disease progression or relapse, as the former is a drug-induced attenuation of response during ongoing treatment, whereas relapse signifies a return of underlying symptoms due to inadequate control rather than pharmacological adaptation.^[16] True tachyphylaxis in this context is characterized by an initial positive response followed by waning efficacy despite stable dosing, excluding cases where symptom worsening stems from natural illness fluctuations.^[17] A key diagnostic criterion for tachyphylaxis is the rapid restoration of drug responsiveness upon withdrawal or a brief washout period, typically within 24 to 48 hours for many agents, confirming the phenomenon's acute and reversible nature rather than permanent adaptation or progression.^[18]^[19] This washout test helps clinicians rule out confounding factors like non-compliance or concurrent illness exacerbation.

Mechanisms

Receptor-Level Mechanisms

Tachyphylaxis at the receptor level primarily arises from mechanisms that attenuate G protein-coupled receptor (GPCR) signaling, including desensitization, internalization, and downregulation. These processes ensure that prolonged agonist exposure does not lead to excessive cellular activation, but they also contribute to the rapid diminution of response observed in tachyphylaxis.^[20] Receptor desensitization occurs rapidly, within seconds to minutes, through phosphorylation of activated GPCRs by G protein-coupled receptor kinases (GRKs), such as GRK2 and GRK3. This phosphorylation, typically on serine and threonine residues in the receptor's intracellular loops and carboxyl terminus, creates binding sites for β-arrestins. β-Arrestin binding sterically hinders further G protein coupling, uncoupling the receptor from downstream signaling pathways like adenylyl cyclase activation. This homologous desensitization is agonist-specific and a key initiator of tachyphylaxis in GPCRs.^[20]^[21]^[22] Following desensitization, receptor internalization reduces the number of GPCRs available on the cell surface. Phosphorylated GPCRs bound to β-arrestin recruit adaptor proteins like AP-2, leading to endocytosis via clathrin-coated pits. For instance, in β2-adrenergic receptors, this clathrin-mediated process forms coated vesicles that sequester the receptor into early endosomes, effectively removing it from agonist access and further attenuating signaling. Internalization not only contributes to short-term tachyphylaxis but also sets the stage for longer-term regulation.^[23]^[24] Over prolonged exposure (tens of minutes to hours), downregulation decreases overall receptor density through reduced protein synthesis and gene expression. Internalized receptors may be targeted to lysosomes for degradation via ubiquitination, while feedback mechanisms inhibit transcription of receptor genes. This often involves negative regulation of transcription factors responsive to GPCR signaling, such as those in cAMP pathways, leading to diminished receptor mRNA and protein levels. Downregulation thus sustains tachyphylaxis by limiting the receptor pool available for resensitization.^[20]^[25] These receptor-level changes manifest in dose-response curves as a rightward shift, where the effective concentration for half-maximal response (EC50) increases, requiring higher agonist doses to achieve equivalent signaling. In the Emax model, this reflects reduced receptor efficacy or availability without altering the maximum response plateau in acute settings, though chronic tachyphylaxis may also lower Emax through downregulation.^[20]^[26]

Cellular and Physiological Mechanisms

Tachyphylaxis often involves intracellular changes downstream of receptor activation, where sustained drug exposure leads to exhaustion of key signaling components within the cell. One primary mechanism is mediator depletion, characterized by the rapid exhaustion of endogenous stores essential for the drug's effect. For instance, repeated stimulation can deplete neurotransmitter vesicles, limiting the availability of transmitters like catecholamines in response to indirect-acting sympathomimetics.^[18] Similarly, second messengers such as cyclic AMP (cAMP) can become depleted through accelerated hydrolysis or insufficient resynthesis, impairing downstream signaling in pathways like those activated by β-adrenergic agonists.^[27] These depletions typically manifest within minutes to hours, distinguishing them from slower adaptive processes. Feedback inhibition represents another critical cellular mechanism, where drug-induced activation triggers negative regulatory loops to restore homeostasis. This can involve heightened phosphatase activity that rapidly dephosphorylates key proteins in signaling cascades, thereby attenuating the response.^[20] In endocrine contexts, such as insulin tachyphylaxis, compensatory release of counterregulatory hormones like glucagon occurs, creating a feedback loop that opposes insulin's glucose-lowering effects and contributes to diminished efficacy over repeated administrations.^[28] These inhibitory processes often build upon initial receptor-level changes, amplifying the overall reduction in responsiveness. At the physiological level, tachyphylaxis encompasses broader adaptations in tissue and organ systems. Vascular endothelium, for example, exhibits reduced responsiveness to vasodilators like organic nitrates due to oxidative stress and impaired nitric oxide bioavailability, leading to diminished relaxation in coronary arteries after continuous exposure.^[29] Neural plasticity in acute settings can also play a role, with synaptic remodeling or altered ion channel function contributing to rapid tolerance in central nervous system responses.^[30] These adaptations highlight how tachyphylaxis extends beyond isolated cells to influence systemic dynamics. Recent pharmacovigilance analyses have further illuminated these mechanisms, identifying mediator depletion as a common factor in tachyphylaxis across more than 15 drug classes, including corticosteroids, opioids, and sympathomimetics, based on FDA adverse event reporting.^[6] Such studies link rapid onset to high-dose regimens, where depletion accelerates under intensive therapeutic pressures, underscoring the need for dosing strategies that mitigate intracellular resource exhaustion.^[6]

Examples in Pharmacology

Central Nervous System Drugs

Tachyphylaxis to central nervous system drugs manifests as a rapid reduction in therapeutic efficacy following repeated administration, often due to receptor desensitization and adaptive changes in neurotransmitter systems. This phenomenon is particularly prominent in psychiatric and addiction contexts, where it complicates long-term treatment and contributes to cycles of escalation or relapse. In psychedelics, opioids, nicotine, and antidepressants, tachyphylaxis arises from mechanisms such as receptor downregulation and altered signaling pathways, impacting dopamine, serotonin, and other key neurotransmitters.^[31] Psychedelics such as lysergic acid diethylamide (LSD) and psilocybin exhibit rapid tachyphylaxis primarily through downregulation of the 5-HT2A serotonin receptor, with tolerance developing within hours of initial exposure. Daily administration of LSD leads to near-complete loss of behavioral effects due to this receptor internalization and reduced responsiveness, a process that parallels general receptor desensitization observed in G-protein-coupled systems. Cross-tolerance between serotonergic psychedelics like LSD and psilocybin occurs because they share the 5-HT2A receptor as their primary target, limiting the efficacy of subsequent doses even across different compounds. This quick onset underscores the need for spaced dosing in therapeutic applications, such as in psychedelic-assisted psychotherapy.^[32]^[33]^[34] Opioids demonstrate acute tachyphylaxis via desensitization of mu-opioid receptors, where repeated morphine doses result in diminished pain relief as receptor phosphorylation and internalization impair G-protein signaling. This rapid tolerance, observable after just a few administrations, contributes to escalating doses in clinical use and is implicated in the neuroadaptations driving addiction cycles, including reward pathway dysregulation. Recent studies from 2025 highlight how mu-opioid receptor desensitization sustains dependence by altering downstream effectors like adenylyl cyclase, perpetuating compulsive use despite initial analgesia. In addiction contexts, this mechanism exacerbates withdrawal and reinforces behavioral patterns, distinguishing tachyphylaxis from slower chronic tolerance.^[35]^[36]^[37] Nicotine induces fast tachyphylaxis at nicotinic acetylcholine receptors (nAChRs), leading to reduced responsiveness after brief exposure and prompting increased smoking frequency to maintain effects. This desensitization depletes dopamine release in reward circuits, such as the ventral tegmental area, where chronic activation shifts from excitation to inhibition, diminishing the reinforcing properties over time. As a result, users escalate intake to counteract the waning stimulant and euphoric effects, fueling nicotine dependence; behavioral studies show this tolerance develops within minutes to hours, correlating with higher daily cigarette consumption. The interplay between nAChR desensitization and dopamine dynamics exemplifies how tachyphylaxis sustains addiction in tobacco use.^[38]^[39]^[40] Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), are associated with the "poop-out" phenomenon, a form of tolerance where initial remission of depressive symptoms fades after months of treatment, affecting approximately 25-30% of patients. This loss of efficacy is linked to downregulation of brain-derived neurotrophic factor (BDNF), a key mediator of neuroplasticity, which initially rises with SSRI use but may decline with prolonged exposure, impairing hippocampal signaling and symptom control. Mechanisms involve adaptive changes in serotonin transporters and downstream neurotrophic pathways, contributing to relapse in major depressive disorder. The prevalence highlights the challenge in maintenance therapy, with studies emphasizing BDNF's role in sustaining antidepressant response.^[16]^[41]^[42]

Respiratory and Cardiovascular Drugs

Tachyphylaxis to beta-2 adrenergic agonists, such as albuterol and salbutamol, manifests as a rapid loss of bronchodilatory effect in the treatment of asthma exacerbations, primarily due to beta-2 receptor internalization following agonist-induced phosphorylation by kinases like GRK2 and subsequent beta-arrestin binding.^[43] This desensitization can occur after repeated dosing, typically within 4-6 administrations during acute episodes, leading to diminished airway relaxation and potentially worsening bronchospasm if not addressed.^[44] In chronic obstructive pulmonary disease (COPD), similar tolerance contributes to challenges in emergency management, with recent analyses indicating that beta-agonist overuse accounts for a notable portion of refractory cases requiring escalation to alternative therapies.^[45] Intranasal decongestants like oxymetazoline, used for symptomatic relief of nasal congestion, induce tachyphylaxis through downregulation of alpha-adrenergic receptors on vascular smooth muscle, resulting in rhinitis medicamentosa characterized by rebound hyperemia and worsened congestion.^[46] This phenomenon typically onsets after 5-10 days of continuous use, as the initial vasoconstrictive response wanes and compensatory vasodilation ensues, often necessitating discontinuation to restore normal nasal physiology.^[47] In cardiovascular pharmacology, nitrates such as nitroglycerin exhibit tachyphylaxis during angina prophylaxis, attributed to depletion of vascular sulfhydryl groups essential for bioactivation into nitric oxide, which impairs vasodilation and reduces anti-ischemic efficacy over continuous exposure.^[48] Clinical strategies to mitigate this include implementing nitrate-free intervals, typically 10-12 hours daily, allowing replenishment of sulfhydryl stores and partial restoration of responsiveness without compromising overall therapeutic coverage.^[49]

Other Therapeutic Classes

Tachyphylaxis to local anesthetics, particularly lidocaine, manifests as a rapid decrease in the duration and intensity of neural blockade following repeated injections of the same dose. This phenomenon arises from the exhaustion of available sodium channels or altered ion dynamics at the nerve membrane, limiting the drug's ability to inhibit nerve conduction effectively. In dental and procedural settings, such as multiple infiltrations during surgery, this can result in inadequate analgesia despite consistent dosing, often requiring dose adjustments or alternative agents to maintain efficacy.^[50]^[9] In diabetes management, acquired insulin resistance can develop through the formation of anti-insulin antibodies that bind and neutralize the hormone, or via downregulation of insulin receptors, leading to diminished glycemic control and increased insulin requirements. This immune-mediated resistance affects approximately 5-10% of type 1 diabetes patients, particularly those on long-term exogenous insulin therapy, and can exacerbate hyperglycemia if not addressed through antibody monitoring or insulin regimen changes.^[51]^[52] Ergotamines, historically used for acute migraine treatment, exhibit tachyphylaxis characterized by vascular receptor desensitization after repeated doses, reducing the drug's vasoconstrictive effects on cranial blood vessels. This tolerance, observed in early clinical studies, limits the utility of ergotamine tartrate for frequent attacks, as patients require escalating doses for relief, prompting a shift toward alternative therapies like triptans.^[53]^[54] Erythropoietin therapy for anemia in chronic kidney disease encounters tachyphylaxis, termed hyporesponsiveness, where repeated administration fails to adequately stimulate erythropoiesis due to feedback inhibition in the JAK-STAT signaling pathway, often compounded by inflammation or iron deficiency. According to the 2024 KDIGO guidelines draft, this reduced response affects dosing strategies in up to 10-20% of patients on dialysis, necessitating evaluation of underlying causes like infections or malignancy before escalating doses.^[55]^[56]

Clinical Management

Prevention Strategies

Preventing tachyphylaxis involves proactive dosing and monitoring approaches to minimize receptor desensitization and downregulation. One key strategy is dose optimization, which entails prescribing the lowest effective dose of a medication to achieve therapeutic benefits while reducing the risk of rapid tolerance development. For instance, in the management of asthma, guidelines recommend using short-acting beta-2 agonists (SABAs) on an as-needed basis rather than continuously to avoid tachyphylaxis, as regular use can lead to diminished bronchodilator response over time.^[57] Intermittent dosing schedules, such as administration every other day for certain beta-agonists, have been shown to delay or prevent receptor internalization and desensitization in preclinical models of airway disease. This approach is particularly relevant for long-acting beta-agonists (LABAs) combined with inhaled corticosteroids, where spacing doses helps maintain efficacy without promoting tolerance. Drug rotation, or alternating between different agents within the same therapeutic class, serves as another preventive measure by preventing sustained receptor overload and allowing recovery from desensitization. For example, in topical corticosteroid therapy for inflammatory skin conditions, alternating high-potency agents on a weekend-off or alternate-day schedule can prevent tachyphylaxis.^[19] Similarly, in scenarios involving repeated agonist exposure, such as in cardiovascular or respiratory treatments, periodic switching has been recommended to preserve drug responsiveness. Patient education plays a crucial role in prevention by promoting adherence to usage guidelines and early recognition of reduced efficacy. For topical decongestants like oxymetazoline, educating patients to limit use to no more than 3 days is essential to avoid rhinitis medicamentosa, a form of tachyphylaxis characterized by rebound nasal congestion due to alpha-adrenergic receptor downregulation. Healthcare providers should instruct patients to monitor for signs such as worsening symptoms despite continued use and to consult promptly if efficacy diminishes, aligning with product labeling and clinical recommendations that emphasize short-term application. This education extends to broader adherence, including tracking symptom response and avoiding overuse in classes prone to tolerance, like sympathomimetics. Pharmacogenetic screening offers a personalized approach to predict and mitigate tachyphylaxis risk by identifying genetic variants that influence drug response. Polymorphisms in the ADRB2 gene, which encodes the beta-2 adrenergic receptor, have been associated with variable bronchodilator responses to beta-agonists in asthma patients, as certain haplotypes (e.g., Arg16-Gly and Gln27-Glu) are linked to heightened desensitization and reduced efficacy over time.^[58] Research indicates potential utility in tailoring therapy for high-risk individuals, though routine genotyping is not yet standard.^[58]

Reversal and Intervention Techniques

One primary strategy for reversing tachyphylaxis involves implementing drug holidays, which entail temporary cessation of the offending agent to permit receptor resensitization and restoration of drug responsiveness.^[59] For antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), brief drug holidays or dose reduction can help restore efficacy in cases of rapid tolerance development.^[16] This approach contrasts with slower-onset tolerance mechanisms, as tachyphylaxis often resolves quickly upon withdrawal. Adjunct agents can mitigate tachyphylaxis by targeting downstream signaling pathways or replenishing depleted mediators. In the case of beta-2 agonists used for asthma and chronic obstructive pulmonary disease, co-administration of phosphodiesterase-4 (PDE4) inhibitors enhances cyclic AMP accumulation and β2-agonist-induced antiinflammatory effects in airway smooth muscle cells.^[60] Similarly, for organic nitrates employed in angina management, antioxidants such as superoxide dismutase (SOD), vitamin C, or dimethyl sulfoxide (DMSO) prevent oxidative stress-induced tolerance by preserving nitric oxide bioavailability and bioactivation pathways.^[61] These interventions are particularly effective when tachyphylaxis arises from mediator depletion or oxidative inactivation, as seen in vascular smooth muscle.^[61] Dose escalation represents a cautious, short-term option for managing established tachyphylaxis, involving incremental increases to overcome diminished responsiveness while monitoring for adverse effects. Clinical guidelines recommend this for antidepressants like selective serotonin reuptake inhibitors, where doubling the dose (e.g., fluoxetine from 20 mg to 40 mg daily) can reinstate therapeutic benefits in cases of rapid tolerance.^[62] However, escalation must balance efficacy gains against heightened risks of toxicity, with regular reassessment to avoid perpetuating dependence.^[16] For intranasal decongestants like oxymetazoline, which commonly induce rhinitis medicamentosa—a form of tachyphylaxis characterized by rebound nasal congestion—reversal focuses on gradual tapering combined with supportive measures. Patients alternate spray use between nostrils over several days, progressing to unilateral or intermittent application, while incorporating saline irrigation to clear mucosa and reduce inflammation; oral alternatives such as pseudoephedrine provide interim relief during withdrawal.^[47] Symptoms typically resolve within 1 to 2 weeks with consistent adherence, though severe cases may require short courses of oral corticosteroids to expedite recovery.^[63] This protocol minimizes rebound exacerbation and promotes long-term mucosal healing.^[64]

References

[1]
16. Receptor Regulation – Principles of Pharmacology – Study Guide
Tachyphylaxis • Tachyphylaxis is a rapid decrease in response to an agonist drug following repeated administration within a brief period; an acute form of ...
[2]
Pharmacology Glossary - Boston University Medical Campus
... tachyphylaxis, a more rapid decline in the effect of a drug. Tolerance can result from multiple mechanisms, including changes in drug metabolism and ...
[3]
Tachyphylaxis | Harvard Catalyst Profiles | Harvard Catalyst
### Summary of Tachyphylaxis from Harvard Catalyst Profiles
[4]
Tachyphylaxis to the Sedative Action of Mirtazapine - PubMed Central
The pharmacological term tachyphylaxis is used to describe rapidly occurring response desensitization, a situation where the biological response to a given drug ...
[5]
Drugs associated with tachyphylaxis: results from a retrospective ...
Jan 9, 2025 · Background: Tachyphylaxis is the rapid development of drug tolerance following repeated administration. Objectives: To evaluate the United ...Missing: definition | Show results with:definition
[6]
Tachyphylaxis/ tolerance to antidepressive medications: a review
Tachyphylaxis is the appearance of progressive decrease in response to a given dose after repetitive administration of a pharmacologically or physiologically ...
[7]
A Proposal for Differentiating Tachyphylaxis and Tolerance - PubMed
Attenuation of drug response with repeated administration is referred to as tachyphylaxis or tolerance, though the distinction between these two is obscured.
[8]
Tachyphylaxis - an overview | ScienceDirect Topics
Tachyphylaxis has been described after central neuraxial blocks, peripheral nerve blocks, and for many different local anesthetic agents (amides, esters, short ...
[9]
TACHYPHYLAXIS Definition & Meaning - Dictionary.com
Tachyphylaxis definition: immediate, temporary immunization against the effects of injection of a toxic extract owing to previous small injections of the ...
[10]
https://www.dictionary.com/browse/tachyphylaxis
[11]
Angiotensin II Type 1 Receptor Tachyphylaxis Is Defined by Agonist ...
Nov 5, 2021 · Tachyphylaxis is a phenomenon characterized by an acute loss of functional response, which usually occurs following repeated agonist stimuli.
[12]
History of the use of ergotamine and dihydroergotamine in migraine ...
May 5, 2008 · Based on the belief that migraine was due to increased sympathetic activity, ergotamine was first used in the acute treatment of migraine by Maier in ...Missing: observation tachyphylaxis
[13]
Functional desensitization of the β2 adrenoceptor is not dependent ...
Jan 5, 2015 · The IUPHAR guide on terms used in Quantitative Pharmacology states that tachyphylaxis and desensitization are “overlapping terms that refer ...
[14]
Differential Phosphorylation, Desensitization, and Internalization of ...
Jan 30, 2013 · One cause of tachyphylaxis is receptor desensitization, usually accompanied by phosphorylation and internalization.
[15]
Identification and Treatment of Antidepressant Tachyphylaxis - NIH
It has been suggested that antidepressant tachyphylaxis is a form of relapse ... ADT tachyphylaxis (or “poop-out”) was initially recognized in patients ...
[16]
Assessing Rates and Predictors of Tachyphylaxis During the ... - NIH
Oct 23, 2013 · ... antidepressant “poop-out ... antidepressant tachyphylaxis that is distinct from previous definitions that equate recurrence and tachyphylaxis.
[17]
Desensitisation and tachyphylaxis - Pharmacology Education Project
The term tachyphylaxis is used to describe desensitization that occurs very rapidly, sometimes with the initial dose. The term tolerance is conventionally used ...
[18]
Tachyphylaxis - an overview | ScienceDirect Topics
The good news is that this is an easily reversible process, particularly if the clinician is mindful of the potential for tachyphylaxis. Weekend-only or ...
[19]
GPCR Desensitization: Acute and Prolonged Phases - PMC
Over hours to days, this may result in decrease receptor expression at the ... Reversible phosphorylation of USP20 at S333 could be a critical factor ...
[20]
GPCR Signaling Regulation: The Role of GRKs and Arrestins
Here we focus on the mechanisms of GRK- and arrestin-mediated regulation of GPCR signaling, which includes homologous desensitization and redirection of ...Missing: tachyphylaxis | Show results with:tachyphylaxis
[21]
G Protein Coupled Receptor Kinases as Therapeutic Targets in ...
Jul 22, 2011 · G protein-coupled receptor kinases (GRKs), in concert with β-arrestins, classically desensitize receptor signal transduction, thus preventing ...
[22]
Trafficking of β-Adrenergic Receptors: Implications in Intracellular ...
In contrast, β2AR undergoes endocytosis primarily through clathrin-dependent pathway. 3.1. Clathrin-Dependent βAR Endocytosis. Clathrin-mediated endocytosis ( ...Missing: seminal papers
[23]
The β2-adrenergic receptor/βarrestin complex recruits the clathrin ...
In the present study we demonstrate the formation of an agonist-induced multimeric complex containing a GPCR, βarrestin 2, and the β2-adaptin subunit of AP-2.Missing: tachyphylaxis seminal
[24]
Downregulation of G protein-coupled receptors - ScienceDirect.com
Jun 1, 2000 · Major advances have been made in understanding mechanisms mediating downregulation of G protein-coupled receptors.
[25]
Angiotensin II Type 1 Receptor Tachyphylaxis Is Defined by Agonist ...
Several GPCRs (G-protein–coupled receptors) have been reported to exhibit tachyphylaxis, which is an acute loss of functional receptor response after ...
[26]
β2-Adrenergic Receptor Signaling and Desensitization Elucidated ...
Here, we use an improved fluorescent biosensor for cAMP to measure second messenger ... Tachyphylaxis, or desensitization, denoting the attenuation of a ...
[27]
Feedback inhibition of insulin gene expression by insulin - PubMed
These studies suggest that insulin has a negative feedback inhibitory effect on its own synthesis. The mechanism of inhibition is unknown. It could be a direct ...Missing: tachyphylaxis | Show results with:tachyphylaxis
[28]
Explaining the Phenomenon of Nitrate Tolerance
Sep 30, 2005 · In summary, continuous systemic therapy with organic nitrates induces tolerance and endothelial dysfunction in patients with coronary artery ...
[29]
Mechanisms of tolerance and tachyphylaxis - Deranged Physiology
Dec 18, 2023 · Tachyphylaxis is defined as a rapid decrease in response to repeated doses over a short time period. Notably, the authors firmly establish that ...Missing: coined | Show results with:coined<|control11|><|separator|>
[30]
Psychedelics - PMC - PubMed Central - NIH
The name psychedelics for these substances was coined by Humphrey Osmond in 1957, connoting that they have a mind-manifesting capability, revealing useful ...
[31]
A Single Dose of LSD Does Not Alter Gene Expression of the ...
Jun 28, 2017 · The repeated use of LSD leads to tolerance that is believed to result from serotonin (5-HT) 5-HT2A receptor downregulation. In rats, daily LSD ...
[32]
Identification of 5-HT2A Receptor Signaling Pathways Responsible ...
... psilocybin and LSD in humans. Responses to ... 5-HT2AR agonists are known to cause receptor downregulation and tolerance or tachyphylaxis.
[33]
Tolerance and Cross-Tolerance among Psychedelic and ... - NIH
Here, we aimed to assess tolerance and cross-tolerance to HTR elicited by psychedelic and nonpsychedelic serotonin 2A receptor (5-HT 2A R) agonists in mice.
[34]
Opioid receptor desensitization: mechanisms and its link to tolerance
Evidence for a different DOR regulation by methadone and morphine was also reported; a pretreatment with methadone but not with morphine produced a cross- ...Missing: tachyphylaxis 2023
[35]
Molecular and cellular basis of mu-opioid receptor signaling - Frontiers
Jun 23, 2025 · This review explores the molecular mechanisms of opioid tolerance, dependence, and withdrawal, emphasizing the need for innovative approaches to address the ...Missing: tachyphylaxis | Show results with:tachyphylaxis
[36]
Analysis of opioid efficacy, tolerance, addiction and dependence ...
Opioid agonists are the most effective treatment for pain, but their use is limited by side effects, tolerance and fears of addiction and dependence.Missing: tachyphylaxis 2023<|separator|>
[37]
Acute Nicotine-Induced Tachyphylaxis Is Differentially Manifest in ...
A single intravenous nicotine injection at 0.1 and 0.3, but not 0.03 mg/kg, significantly increased neuronal activity in many neocortical areas.<|control11|><|separator|>
[38]
Long-Term Nicotine Exposure Depresses Dopamine Release in ...
These data indicate that nicotine exposure, as occurs with smoking, has major effects on cellular mechanisms linked to α6β2* nAChR-mediated dopamine release.
[39]
Going up in Smoke? A Review of nAChRs-based Treatment ...
Nicotine also causes rapid desensitization of the receptor or tachyphylaxis ... Genetics of nicotinic acetylcholine receptors: Relevance to nicotine addiction.
[40]
Tolerance to Stimulant Medication for Attention Deficit Hyperactivity ...
Jul 22, 2022 · The researchers noted that the time course of acute tachyphylaxis suggests that acute tolerance would dissipate between the afternoon dose and ...Missing: DAT | Show results with:DAT
[41]
Unravelling the effects of methylphenidate on the dopaminergic and ...
Here, we focus on methylphenidate (MPH), which binds to the dopamine transporter (DAT) and the norepinephrine transporter (NET), to unravel its effects on ...
[42]
Long-Term Stimulant Treatment Affects Brain Dopamine Transporter ...
Twelve months of methylphenidate treatment increased striatal dopamine transporter availability in ADHD (caudate, putamen and ventral striatum: +24%, p<0.01).Missing: tachyphylaxis internalization
[43]
BDNF as a Mediator of Antidepressant Response - MDPI
This narrative review provides an up-to-date overview of the interplay between antidepressant treatment and Brain-Derived Neurotrophic Factor (BDNF) signaling.Missing: tachyphylaxis | Show results with:tachyphylaxis
[44]
BDNF — a key transducer of antidepressant effects - PMC
An increase in hippocampal and cortical expression of BDNF mRNA parallels the antidepressant-like response of conventional antidepressants such as SSRIs.Missing: tachyphylaxis downregulation prevalence
[45]
Beta-Adrenergic Agonists - PMC - PubMed Central - NIH
Inhaled β 2 -adrenoceptor (β 2 -AR) agonists are considered essential bronchodilator drugs in the treatment of bronchial asthma.Beta-Adrenergic Agonists · 2. Adrenergic Control Of Asm... · 5. β-Ar Dysfunction
[46]
Albuterol-induced downregulation of Gsα accounts for pulmonary β2 ...
β2-Adrenoceptor agonists are the most effective bronchodilators currently available and exhibit efficacy irrespective of the mediator(s) evoking bronchospasm.
[47]
[PDF] 2025 Report. - Global Initiative for Chronic Obstructive Lung Disease
Nov 15, 2024 · (1044,1045) There is no evidence that beta-blockers should be used in people with COPD who do not have a cardiovascular indication for their ...
[48]
Fluticasone Reverses Oxymetazoline-induced Tachyphylaxis of ...
Nov 12, 2009 · The present study shows that oxymetazoline-induced tachyphylaxis of response and associated rebound congestion is reversed by fluticasone.
[49]
Rhinitis Medicamentosa - StatPearls - NCBI Bookshelf - NIH
Sep 4, 2023 · Rhinitis medicamentosa (RM), also known as 'rebound congestion' is inflammation of the nasal mucosa caused by the overuse of topical nasal decongestants.Missing: downregulation | Show results with:downregulation
[50]
Mechanisms of nitrate tolerance - PubMed - NIH
Classical hypotheses of nitrate tolerance suggest the phenomenon to result from vascular depletion of critical sulfhydryl groups, which are necessary to bring ...Missing: tachyphylaxis intervals
[51]
Challenges with nitrate therapy and nitrate tolerance - PubMed
By providing a nitrate-free interval, or declining nitrate levels at night, one can overcome or reduce the development of tolerance, but cannot provide 24-h ...
[52]
peripheral nerve blocks and infiltration anesthesia in rats - PubMed
Tachyphylaxis to peripheral neural blockade was determined with repeated injections of a constant dose of lidocaine in three experimental models: sciatic ...
[53]
Diagnosis and treatment of anti‐insulin antibody‐mediated labile ...
Anti‐insulin antibodies can cause dysglycaemia in exogenous insulin‐naïve people ('insulin autoimmune syndrome') and in people with insulin‐treated diabetes.Missing: tachyphylaxis | Show results with:tachyphylaxis
[54]
Insulin Antibodies | Johns Hopkins Diabetes Guide
Sep 4, 2017 · This reference provides an overview of the immunologic factors in the development of insulin antibodies and reviews its relationship toward diabetes ...Missing: tachyphylaxis | Show results with:tachyphylaxis
[55]
ERGOTAMINE TOLERANCE IN PATIENTS WITH MIGRAINE | JAMA
In 1922 alkaloid ergotamine tartrate was developed, and several years after this its use in the treatment of migraine was suggested.
[56]
Development of Tolerance to Ergot Alkaloids in a Patient with ...
Substitution of dihydroergotamine for ergotamine was also attempted several times during the period in which tolerance developed, and it became apparent that ...
[57]
[PDF] kdigo 2025 clinical practice guideline for anemia in chronic kidney ...
ESA hyporesponsiveness. Practice Point 3.7.1: In people with anemia and CKD G5D and CKD not receiving dialysis with initial or subsequent ESA hyporesponsiveness ...
[58]
Anemia of chronic disease - PubMed
In addition, inappropriate erythropoietin levels or hyporesponsiveness to erythropoietin and reduced red blood cell survival contribute to the anemia.<|separator|>
[59]
What Does Drug Tolerance Mean, and When Should You Worry?
Oct 22, 2024 · It's possible to reverse the effects of drug tolerance through strategies like a drug holiday, in which you stop using the drug and then ...Missing: psychedelics | Show results with:psychedelics
[60]
(PDF) Tolerance to Lysergic Acid Diethylamide - ResearchGate
Jun 2, 2025 · Once established, tolerance cannot be overcome even if the initial dose is quadrupled. Mental tolerance to LSD generalizes to psilocybin and ...Missing: holiday | Show results with:holiday<|separator|>
[61]
Inhibitors of Phosphodiesterase 4, but Not ... - PubMed
Our data show that inhibitors of PDE4, but not PDE3, increase β2-agonist-induced cAMP and induce MKP-1 mRNA expression and protein up-regulation. When cAMP was ...
[62]
New approaches to overcome tolerance to nitrates - PubMed
Generation of tachyphylaxis could be suppressed or even avoided by supplementation of appropriate antioxidants (SOD, vitamin C, DMSO, beta-blockers with ...
[63]
Tachyphylaxis In Antidepressants: The Science Behind Treatment ...
Oct 21, 2025 · Studies have found that patients receiving selective serotonin reuptake inhibitors (SSRIs) experience higher rates of tachyphylaxis (14.1 ...
[64]
Rebound Congestion: How Long Does It Last? (& 5 More Questions ...
Mar 8, 2022 · If you've been using a nasal decongestant spray for more than three days, you might have rebound congestion. Get your questions about it ...Missing: intranasal | Show results with:intranasal
[65]
Rhinitis Medicamentosa Treatment & Management
Mar 31, 2025 · The oral corticosteroids are often used for 5–10 days, with nasal corticosteroids started at the same time and continued until the process is ...